Bertilimumab
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT01671956)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- EotaxinINHIBITOR
CCL11 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109103 ↗
Also known as
- bertilimumab
- bertilimumab
- cat-213
- cat-213
- ico-008
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02226146 | Phase 2 | Feb 1, 2016 | Immune Pharmaceuticals, Tel Aviv University |
| NCT01671956 | Phase 2 | Jul 1, 2015 | Hebrew University, Immune Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Pharmaceuticals | For profit | 2 | 2 | 1 | 2015 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1